On August 7, Natera surged 19.24% in regular trading, trading at $316.0/share, with turnover of $112 million. The rally was driven by a strong Q2 earnings report that significantly exceeded market expectations on multiple fronts.
Natera reported Q2 revenue of $752.8 million, up 37.7% year-over-year, substantially beating the consensus estimate of $661.2 million. Adjusted loss per share came in at $0.47, narrowing from $0.74 a year earlier and better than the $0.49 loss expected by analysts. The company also raised its full-year revenue guidance to $2.85 billion-$2.91 billion, up from the prior range of $2.74 billion-$2.82 billion and above the Street estimate of $2.80 billion. Following the results, RBC Capital raised its price target on Natera to $350 from $275 while maintaining an Outperform rating.
The results come amid a series of positive developments for Natera's core Signatera product, including EU IVDR certification, Japan PMDA approval for colorectal cancer use, NCCN Category 1 recommendation in bladder cancer, and FDA approval as a companion diagnostic, further solidifying its leadership in molecular residual disease testing.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments